Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the outcome of Sarepta Therapeutics' relationship with the Duchenne patient advocacy organization by December 31, 2024?
Relationship improves • 25%
Relationship deteriorates • 25%
Relationship remains the same • 25%
No official statement • 25%
Official announcements from Sarepta Therapeutics or the advocacy organization
Sarepta ($SRPT) Faces Backlash for Censoring Critical Duchenne Advocacy Video
Jul 29, 2024, 12:18 PM
Sarepta Therapeutics ($SRPT) has come under scrutiny for demanding a prominent Duchenne muscular dystrophy patient advocacy organization censor a video that contained pointed criticism of its new gene therapy. The video, which was critical of Sarepta's approach and its impact on patients, was subsequently taken down. This incident, reported by STAT, has raised questions about the relationship between drugmakers and patient advocacy groups. The news has sparked discussions about the influence pharmaceutical companies exert over advocacy organizations and the potential implications for patient care and transparency.
View original story
Yes • 50%
No • 50%
Sarepta stock up >10% • 25%
Arrowhead stock up >10% • 25%
Both stocks up >10% • 25%
Neither stock up >10% • 25%
Clinical trial initiation • 25%
Regulatory approval • 25%
New program announcement • 25%
No major milestone • 25%
Below $166 • 33%
$166 to $213 • 33%
Above $213 • 34%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Major changes • 25%
Discontinues gene therapy • 25%
No changes • 25%
Minor changes • 25%